Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure  by Martin, Fernando L. et al.
Kidney International, Vol. 67 (2005), pp. 1723–1730
HORMONES – CYTOKINES – SIGNALING
Natriuretic and antialdosterone actions of chronic oral NEP
inhibition during progressive congestive heart failure
FERNANDO L. MARTIN, TRACY L. STEVENS, ALESSANDRO CATALIOTTI, JOHN A. SCHIRGER, DANIEL D.
BORGESON, MARGARET M. REDFIELD, ANDREAS LUCHNER, and JOHN C. BURNETT, JR.
Cardiorenal Research Laboratory, the Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota
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inhibition during progressive congestive heart failure.
Background. Neutral endopeptidase (NEP) degrades atrial
natriuretic peptide (ANP) that via cyclic guanosine monophos-
phate (cGMP) is natriuretic and aldosterone-inhibiting. We hy-
pothesized that chronic oral NEP inhibition (NEPI), initiated
in early experimental congestive heart failure (CHF), would
delay onset of decreases in sodium excretion during the pro-
gression of CHF and, in the severe phase, suppress aldosterone
activation and reduce the magnitude of sodium retention. We
also hypothesized that chronic NEPI during progressive CHF
(PCHF) would improve the natriuretic response to acute vol-
ume expansion.
Methods. In a novel canine model that progresses over 38 days
from early to moderate and finally severe CHF, we defined the
actions of chronic NEPI (candoxatril, 10 mg/kg, orally, twice a
day) upon cardiorenal and neurohumoral function as well as
the clinical well being of treated and untreated dogs in CHF.
Results. From baseline through the moderate phase of CHF,
NEPI maintained sodium excretion. In contrast, in moderate
CHF, sodium excretion was reduced compared to the early
phase in the controls. In severe CHF, sodium excretion was
higher with NEPI compared to control. Chronic NEPI also re-
sulted in lower plasma aldosterone as compared to controls. In
severe CHF, the natriuretic response to acute saline volume ex-
pansion was enhanced with oral NEPI as compared to control.
Conclusion. This study supports the conclusion that chronic
oral NEPI delays the onset of reduction in sodium excretion
during the transition from early to severe CHF in this model
of PCHF. This therapeutic strategy also improved the natri-
uretic response to acute volume expansion in severe CHF while
enhancing ANP and suppressing aldosterone activation. Thus,
these studies demonstrated a selective renal and adrenal ac-
tion of chronic NEPI in heart failure indicating a therapeutic
potential.
Chronic congestive heart failure (CHF) is a syndrome
that progresses from early asymptomatic left ventricu-
lar dysfunction (LVD) to severe symptomatic CHF. In-
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creasing evidence supports the concept that the kidney
plays a key role as a mechanism which may contribute
to progression of heart failure. Early LVD is character-
ized by activation of atrial natriuretic peptide (ANP)
with maintenance of sodium balance without increases of
the renin-angiotensin-aldosterone system [1]. By mecha-
nisms which remain unclear, early LVD evolves through a
moderate phase with the onset of mild sodium retention
and finally to severe CHF with activation of vasocon-
strictor, growth promoting, and sodium retaining factors.
Indeed, increased sodium retention with edema forma-
tion is a hallmark of symptomatic CHF underscoring a
key role of the kidney in this disorder.
A role for endogenous ANP and other endogenous
natriuretic peptides has been advanced in early heart fail-
ure in part based upon their natriuretic and aldosterone-
inhibiting actions [2]. First, the genetic disruption in mice
of the natriuretic peptide A receptor, which binds ANP,
results in an impaired renal natriuretic response to acute
volume expansion underscoring the importance of the
natriuretic peptides in maintaining sodium homeostasis
[3, 4]. In experimental early LVD, acute administration of
a natriuretic peptide receptor antagonist accelerated the
progression to severe CHF as demonstrated by enhanc-
ing the onset of sodium retention [5]. More recently, we
reported that acute intravenous brain natriuretic peptide,
which binds to the same receptor than ANP, suppresses
furosemide-induced increases in aldosterone in experi-
mental CHF [6].
Neutral endopeptidase 24.11 (NEP) is a zinc-
dependent ectoenzyme that has been shown to be in-
volved in the metabolism of ANP and other peptides
[7, 8] NEP has a wide tissue distribution, including the
kidney, lung, endothelial cells, and brain. The highest
concentrations of NEP have been localized in brush bor-
der vesicles of the renal proximal tubule [9]. Repeated
studies have demonstrated that acute NEP inhibition
(NEPI) in experimental models of CHF results in an
increase in sodium excretion with increases in urinary
ANP and cyclic guanosine monophosphate (cGMP) [10].
Studies in human heart failure and chronic renal failure
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utilizing acute NEPI have also demonstrated improve-
ment in sodium excretion [11–13]. We reported that the
natriuretic action of NEPI in experimental CHF is im-
portantly affected by the stage of CHF. Specifically, acute
NEPI was most natriuretic in the early phases of CHF as
compared to severe CHF or even compared to normal
where endogenous ANP in plasma is not increased [10]
Not addressed to date is the crucial question of whether
chronic oral NEPI could delay the onset of impairments
in sodium excretion and retard the activation of aldos-
terone during the progression of CHF, which are two
important end points in CHF. Demonstration of disease
delaying properties of chronic oral NEPI would serve as
a rationale to revisit this potentially important agent in
CHF. Thus, these studies represent an important exten-
sion from previous work.
The current study was therefore designed to address
the hypothesis that chronic oral NEPI, initiated in early
experimental CHF, would delay onset of decreases in
sodium excretion during the progression of CHF and,
in the severe phase, suppress aldosterone activation
and reduce the magnitude of sodium retention. We
also hypothesized that chronic NEPI during progressive
CHF (PCHF) would improve the natriuretic response to
acute volume expansion in severe CHF. To address this
hypothesis, we utilized a novel canine model of experi-
mental CHF that simulates the human spectrum of pro-
gressive CHF (PCHF) [14–16]. This model gradually
evolves, through gradual changes in ventricular pacing
rate from a stage of compensated ventricular dysfunc-
tion with elevated ANP and cGMP without sodium re-
tention, through a moderate phase with the onset of mild
sodium retention and then to severe CHF which is char-
acterized by profound sodium retention with activation
of aldosterone and an impaired renal natriuretic response
to acute volume expansion.
METHODS
Animal model
In a sterile surgical suite, under pentobarbital sodium
anesthesia (30 mg/kg intravenously for induction and dos-
ing as needed for maintenance of anesthesia) and artifi-
cial ventilation (Harvard Respirator) (Harvard Apara-
tus, Millis, MA, USA) with 5 mL/min supplemental oxy-
gen, 15 mongrel male dogs (average weight 20 kg) under-
went implantation of a programmable cardiac pacemaker
(Medtronic, Minneapolis, MN, USA). By a left thoraco-
tomy and a 1 to 2 cm pericardiotomy, the heart was ex-
posed and a screw-in epicardial pacemaker lead was im-
planted into the right ventricle. The pacemaker lead was
connected to a pulse generator which was implanted sub-
cutaneously in the chest wall. Pacing capture was verified
intraoperatively. The pericardium was sutured close with
great care not to distort the anatomy of the pericardium.
Following the sterile surgical procedure and extuba-
tion, each dog spent the next 24 hours in a monitored
recovery area. Butorphanol (0.3 mg/kg intramuscularly
twice) was used for postoperative analgesia. After dis-
charge from the recovery area, dogs were housed in
metabolic cages which permitted continuous urine col-
lection. A recovery period of 14 days was allowed. Pro-
phylactic antibiotic treatment with 225 mg clindamycin
subcutaneously and 400,000 U procaine penicillin G plus
500 mg dihydrostreptomycin intramuscularly (Combi-
otic) (Pfizer, Inc., New York, NY, USA) was adminis-
tered preoperatively and on the first two postoperative
days. Dogs were fed a fixed sodium diet (58 mEq/day)
(Hill’s I-D) and allowed water ad libitum. Appetite, ac-
tivity, body temperature, and condition of surgical skin
sites were documented daily. All studies were conducted
in the conscious state and in accordance with the Animal
Welfare Act.
PCHF was produced by incremental rapid ventricular
pacing as previously reported. [14–16] On postoperative
day 15, dogs underwent rapid ventricular pacing at 180
beats per minute (bpm) and continued at this rate for 10
days. This 10-day pacing period at 180 bpm induces ex-
perimental early CHF, as previously described, which is
characterized by ventricular dysfunction and maintained
sodium balance [17]. The pacing rate was then increased
at 7-day intervals to 200, 210 (moderate phase, defined as
the onset of mild sodium retention), 220, and 240 bpm (se-
vere CHF defined as profound sodium retention and im-
paired natriuretic response to acute volume expansion).
Pacemaker capture was verified in every dog at each stage
of ventricular dysfunction, including severe CHF.
NEPI
Candoxatril (Pfizer Central Research, Sandwich, Eng-
land) is the orally active prodrug of candoxatrilat, a se-
lective inhibitor of NEP. Candoxatril was initiated on day
5 of the early CHF period to six dogs undergoing the
PCHF protocol (NEPI group). This was orally adminis-
tered throughout the protocol on a twice daily basis at a
dose of 10 mg/kg, orally. This dose was selected to achieve
plasma levels of inhibitor exceeding IC95 throughout the
dosing period. The control group (N = 9) received no
treatment.
Echocardiography. A two-dimensional and two-
dimensional–guided M-mode echocardiogram (Toshiba,
Tokyo, Japan) was performed from the right parasternal
window of the dog at baseline (pre-CHF), early CHF
(day 10), moderate phase (day 24), and severe CHF
(day 38). Left ventricular end-diastolic (LVED) and end-
systolic (LVES) dimensions were measured from the
two-dimensional–guided M-mode tracings. Echocardiog-
raphy was performed by a single echocardiographer with
over 5 years of experience performing echocardiography
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in humans and dogs. Echocardiograms were performed in
the conscious state with the dog unrestrained and stand-
ing quietly. All images were obtained with the pacemaker
deprogrammed for a total imaging period of less than
10 minutes. Three cardiac cycles were measured and the
average of the three measurements was taken. No cy-
cles after a premature or paced premature beat were
used for analysis. Echocardiographic data were utilized
to calculate left ventricular ejection fraction as [(LVED2
– LVES2)/LVED2] dimension.
Cardiovascular and renal function and responses to acute
volume expansion
As part of the protocol, two acute experiments were
conducted. These were performed at baseline, with nor-
mal ventricular function and for comparison at comple-
tion of the protocol, with severe CHF. The night before
the acute experiment the animals were fasted and allowed
access to water ad libitum. The day of the acute experi-
ment, the dogs were briefly anesthetized with thiopen-
tal sodium (15 mg/kg, intravenously) to allow sterile
percutaneous placement of a flow-directed balloon tip
pulmonary artery catheter (model 93131-7F) (American
Edwards Laboratories, AHS del Caribe, Anasco, Puerto
Rico) via an external jugular vein for measurement of car-
diac output and filling pressures. A catheter was inserted
in the urinary bladder for urine collection. After dogs
fully regained consciousness, an equilibration period of
60 minutes was allowed before initiating the acute study.
This consisted of a 30-minute baseline clearance and a 1-
hour volume expansion clearance. Hemodynamics were
measured, blood was drawn, and urine was collected for
electrolytes, assays, and urine volume as described below
at the end of each clearance. All of these measurements
were performed with the pacer on.
Cardiac hemodynamic parameters measured included
right atrial, pulmonary artery, and pulmonary capillary
wedge pressures and cardiac output. Cardiac output (CO)
was determined by thermodilution (model 9510-A com-
puter) (American Edwards Laboratories, Irvine, CA,
USA) and measured four times and averaged. At the
completion of the acute study the pulmonary catheter
was removed and pressure applied for homeostasis, fol-
lowed by a compression Vet Wrap which was removed 4
hours after application.
Glomerular filtration rate (GFR) was measured by in-
ulin clearance. Urinary and plasma inulin concentrations
were measured by the anthrone method [18].
Acute volume expansion was initiated following the
baseline clearance in severe CHF. Normal saline was
infused through the right atrial port of the Swan-Ganz
catheter at a rate to equal a total volume of 10% of body
weight over 60 minutes of volume expansion.
Clinical functional score. A clinical assessment scale
was developed and served as an additional means of as-
sessing the effects of progressive LVD. This score was as-
signed by two different observers to each dog at baseline
and at each interval echocardiography was performed.
The six criteria were as follows: (1) slows/stops with brisk
100-yard walk; (2) eats <100% of daily meal; (3) respira-
tory rate doubled from baseline; (4) muscle atrophy/loss
of body fat; (5) clinical ascites; and (6) left ventricular
ejection fraction <50% baseline.
For each criterion that the dog manifests, a score of 1
was given. Scores may range from zero if all the criteria
were absent, to six if all the criteria were present.
Plasma, urinary standard analysis, and
radioimmunoassay (RIA) determination
Blood was drawn at baseline (pre-CHF), at each pacing
interval change and during the acute study. Samples were
collected in prechilled heparin and ethylenediaminete-
traacetic acid (EDTA) tubes and immediately placed on
ice. After centrifugation at 2500 rpm at 4◦C, the plasma
was decanted and stored at −20◦C until analysis. Urinary
studies were assessed as described above with the acute
studies and with 24-hour urine collections. Two consecu-
tive 24-hour collections were performed at baseline and
at the last 2 days of each pacing interval. All urine was
collected on ice. Plasma and urinary electrolytes were
measured using ion-selective electrodes (Beckman In-
struments, Brea, LA, USA). Specific plasma assays an-
alyzed included ANP, cGMP, and aldosterone. Plasma
aldosterone was determined by RIA [19]. Plasma and uri-
nary ANP and cGMP data were measured by a specific
RIA as previously described [20, 21]. Urine for cGMP
measurement was heated to >90◦ before storage. Spe-
cific intra- and interassay coefficients for variation are,
respectively, ANP 6% and 9%, cGMP 2.5% and 4.2%,
and aldosterone 4% and 6%.
Statistical analysis
Results of the quantitative studies were expressed as
mean ± SEM. Data were assessed by Student unpaired
t tests and factorial analysis of variance (ANOVA) for
comparisons between groups, Student paired t tests for
single comparisons of absolute changes within each group
and by ANOVA for repeated measures, followed by
Fisher least significant difference test when appropriate.
Statistical significance was accepted as P < 0.05.
RESULTS
Sodium excretion and neurohumoral activation during
PCHF
Temporal changes in plasma ANP, cGMP, aldosterone,
and urinary sodium excretion are illustrated in Figure 1.
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Fig. 1. Neurohumoral and sodium excretion data in control () (N = 9) and neutral endopeptidase inhibition (NEPI) () (N = 6) groups.
(A) Plasma atrial natriuretic peptide (ANP). (B) Cyclic 3′-5′-guanosine monophosphate (cGMP). (C) Aldosterone (Aldo). (D) Urinary sodium
excretion (UNaV). Data are expressed as mean ± SEM. PCHF is progressive congestive heart failure.
ANP increases progressively and significantly as heart
failure evolves in the untreated group; while in the NEPI
group, ANP increases significantly only in the moderate
phase and then decreases in severe CHF as compared to
the moderate phase but remains elevated when compared
to baseline (Fig. 1A). Plasma cGMP increased in both
untreated and NEPI group. However, its increases were
significantly higher in the NEPI group as compared to
control in the early and severe phases of CHF (Fig. 1B).
Plasma aldosterone significantly increased in the control
group in severe CHF. Importantly, aldosterone was not
activated in the NEPI group and remained significantly
lower as compared to control in severe CHF (Fig. 1C).
In the control group, urinary sodium excretion de-
creased in the moderate phase of CHF with an even more
profound decline in the severe CHF period. NEPI de-
layed the onset of sodium retention, as sodium excretion
during the moderate phase was not different from base-
line or the early phase of CHF. However, in the control
group, it was significantly lower in the severe phase of
CHF as compared to the other stages of CHF or the
NEPI group (Fig. 1D). Importantly, overall sodium ex-
cretion in severe CHF was greater in the NEPI group as
compared to the control group (P < 0.05, between the two
groups).
Figure 2 illustrates the response to acute volume ex-
pansion in both groups with severe CHF. The increase in
sodium excretion with acute volume expansion in severe
CHF was greater in the chronic NEPI group as compared
to control (Fig. 2A). This was also associated with greater
increases in both urinary ANP and cGMP excretion
(Fig. 2B and C).
Left ventricular function during the progression of CHF.
Ejection fraction, as determined by echocardiography,
was similar at baseline in both groups and decreased with
progressive LVD (Fig. 3A). In the moderate phase ejec-
tion fraction was modestly but significantly greater in the
NEPI-treated group.
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Fig. 2. Responses to acute saline volume expansion in control () (N
= 9) and neutral endopeptidase inhibition (NEPI) () (N = 6) groups
with severe congestive heart failure. Abbreviations are: UNaV, urinary
sodium excretion; UNAP, urinary atrial natriuretic peptide excretion;
UcGMP, urinary cyclic 3′-5′-guanosine monophosphate excretion. Data
represent the change () from the baseline clearance to the volume
expansion clearance and are expressed as Mean ± SEM. ∗P < 0.05
NEPI vs. control.
Clinical functional score. From a baseline score of zero
the clinical score remained unchanged in the early phase
of CHF in both the NEPI and control groups. In con-
trast, in the moderate phase, the clinical score increased
in the control group reflecting progressive functional im-
pairment while the clinical score in the NEPI group re-
mained unchanged from baseline (Fig. 3B). In severe
CHF, the clinical score increased in both groups but re-
mained lower in the NEPI group.
Cardiorenal function at baseline and in severe CHF
Cardiorenal function at baseline and severe CHF is
reported in Table 1 for both control and NEPI groups.
There were no differences in baseline values between the
two groups with the exception of mean arterial pressure
(MAP) where the NEPI group had a slightly higher blood
pressure prior to induction of CHF as compared to the
control group. PCHF was characterized by decreases in
MAP, CO, GFR, renal plasma flow, and by increases in
right atrial pressure and pulmonary capillary wedge pres-
sure in both NEPI and control group.
There were no changes in urinary ANP in the NEPI
and control group throughout the progression of CHF.
Urinary cGMP increased in both groups in the severe
stage of CHF as compared to baseline.
DISCUSSION
The current study was designed to test the hypoth-
esis that chronic oral NEPI, initiated in early experi-
mental CHF, would delay onset of decreases in sodium
excretion during the progression of CHF and, in the se-
vere phase, suppress aldosterone activation and reduce
the magnitude of sodium retention. Also, we hypothe-
sized that chronic NEPI during PCHF would improve
the natriuretic response to acute volume expansion in
severe CHF. Our findings support the hypothesis that
NEPI initiated during early experimental CHF delays the
onset of sodium retention. Specifically, the maintenance
of sodium excretion was prolonged by oral NEPI. In
addition, in severe CHF a sustained renal action of NEPI
was demonstrated as the magnitude of the decrease in uri-
nary sodium excretion retention was significantly reduced
compared to the untreated group. This enhancement of
sodium homeostasis was associated with greater increases
in cGMP, the second messenger of ANP and other natri-
uretic peptides, as compared to untreated group during
moderate and severe CHF, respectively. Complementing
these renal and humoral actions of NEPI was the ob-
servation that the activation of aldosterone was attenu-
ated in severe CHF. Furthermore, in severe CHF, NEPI
also improved the impaired natriuretic response to acute
saline volume expansion. Finally, during the moderate
phase only, left venticular ejection fraction was moder-
ately greater in the NEPI group compared to control
while the clinical score was improved both in moderate
and severe CHF. These findings support the therapeu-
tic potential of chronic NEPI as a renal acting therapy
which enhances renal sodium handling in CHF together
with aldosterone inhibition.
In early CHF, chronic oral NEPI resulted in greater
activation of cGMP compared to the control group, with-
out a significant increase in plasma ANP. This increase
in plasma cGMP may be explained by a greater interac-
tion of ANP and maybe other members of the natriuretic
peptide family with their receptors in a number of target
organ systems due to local inhibition of NEP. At this early
phase of LVD in both control and NEPI groups, sodium
excretion is not decreased and aldosterone is not acti-
vated which mimics human asymptomatic CHF. In both
groups, there was a reduction in left ventricular ejection
fraction and an absence of symptoms as assessed by the
clinical score.
In the moderate phase, chronic NEPI maintained
sodium excretion, while it decreased modestly in the con-
trol group, consistent with the transition phase of evolv-
ing heart failure. Chronic oral NEPI also induced the
greater increase in plasma ANP as compared to the con-
trol group, maintaining elevation of cGMP. Taken to-
gether, these data demonstrate that NEPI delayed the
onset and magnitude of a reduction in sodium excretion
during the progression to severe CHF. This effect could
be due, at least in part, to the enhancement of the endoge-
nous ANP, as indicated by a greater increase in plasma
ANP and cGMP in this moderate stage of CHF. The
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Fig. 3. (A) Changes in ejection fraction (%)
in the progression of congestive heart failure
(CHF) in control () (N = 9) and NEPI ()
(N = 6) groups. (B) Clinical functional score
in the progression of CHF in control () (N =
9) and NEPI () (N = 6) groups. Data are ex-
pressed as mean ± SEM. PCHF is progressive
congestive heart failure.
Table 1. Cardiorenal function at baseline and severe heart failure
Baseline Severe CHF
Mean arterial pressure mm Hg Control 112 ± 3 99 ± 4a
NEPI 124 ± 2b 94.3 ± 3a
Cardiac output L/min Control 5.0 ± 4 2.4 ± 2a
NEPI 5.4 ± 4 2.6 ± 2a
Right arterial pressure mm Hg Control 6 ± 1 13 ± 2a
NEPI 6 ± 1 13 ± 2a
Pulmonary capillary wedge pressure mm Hg Control 11 ± 1 23 ± 2a
NEPI 12 ± 1 25 ± 2a
Glomerular filtration rate mL/min Control 132 ± 21 62 ± 10a
NEPI 122 ± 12 65 ± 6a
Renal plasma flow mL/min Control 520 ± 170 180 ± 20a
NEPI 525 ± 165 176 ± 18a
UANP pg/mL Control 32.2 ± 13.4 24.8 ± 9.4
NEPI 33.8 ± 18 50.2 ± 26
UcGMP pmol/mL Control 1364 ± 216 2558 ± 37a
NEPI 1423 ± 213 3311 ± 253a,b
Abbreviations: NEPI, neutral endopeptidase inhibition; UANP, urinary ANP; UcGMP, urinary cGMP. Data are expressed as mean ± SEM.
aP < 0.05 vs baseline, bP < 0.005 vs. control.
renal natriuretic actions of chronic oral NEPI observed
in the current study during the moderate phase of CHF
is consistent with a previous study by Chen et al [10] that
reported that acute intravenous NEPI in mild CHF re-
sulted in marked improvement of sodium excretion that
exceeded that observed in severe CHF as well as in nor-
mal controls. In this moderate phase, a clinical score of
2 was noted in the control group which was absent in
the preceding early phase and was consistent with symp-
tomatic LVD. The clinical score in the NEPI group was
lower than the control group in this moderate phase. Left
ventricular ejection fraction was reduced in both groups
but the NEPI group had a significantly higher ejection
fraction than the control group, although this too was
modest.
In the severe phase of CHF the level of sodium excre-
tion was higher in the NEPI group compared to the con-
trol group. Further, the renal response to acute volume
expansion was also greater in the NEPI group compared
to the control group. This enhanced response to volume
expansion in the NEPI group occurred in association with
greater urinary ANP and cGMP excretion. The mecha-
nism of these renal actions most likely are linked to en-
hanced renal action of filtered plasma ANP at the level of
the renal tubule as urinary cGMP was significantly higher
in severe CHF as compared to the untreated group in the
absence of any higher level of GFR or renal plasma flow
in the NEPI group. This is underscored especially during
acute volume expansion urinary ANP and cGMP excre-
tion were also greater in the presence of NEPI.
Martin et al: Renal actions of NEPI in experimental CHF 1729
In patients with heart failure, systemic congestion is
associated with the rate of hospitalization. Therefore, it
is important to have tools that improve sodium excre-
tion in the different phases of heart failure and in acute
volume expansion that will not only improve symptoms
but also prevent hospitalization and mortality [22, 23].
Treating congestion is an increasingly important target
as suggested by the ACTIV study where a vasopressin
antagonist was shown to help manage systemic conges-
tion in hospitalized patients with heart failure and volume
overload [24]
An additional major finding is that chronic NEPI re-
duced markedly the activation of aldosterone, confirming
the results reported by Rademaker et al [25] where in a
model of ovine pacing induced heart failure, they found
a decrease in plasma aldosterone with a short term 4
day treatment period with a NEPI infused intravenously.
Based upon the known high expression of the natriuretic
peptide A receptor in the zona glomerulosa of the adrenal
gland, one could speculate the mechanism of aldosterone
suppression with chronic NEPI may involve ANP. This is
also supported by the findings of Rebuffat et al [26] who
reported that a 7-day infusion of ANP in rats induced
atrophy of the zona glomerulosa cells and also inhibited
their secretory activity. It is well established that aldos-
terone increases tubular sodium reabsorption in inner
medullary collecting duct cells which is also the site of
action of ANP. Therefore, enhancing ANP presence by
inhibiting its degradation in the proximal nephron where
NEP is abundant may result in greater delivery to the
terminal nephron, thus antagonizing the actions of al-
dosterone while also decreasing aldosterone release. This
should result in improved handling of sodium by the kid-
ney. Indeed, our studies support such a conclusion. In the
severe phase, the clinical score worsened but it was sig-
nificantly lower in the NEPI group. The ejection fraction
in this phase was reduced and there was no difference
between the two groups.
While sodium excretion was improved with chronic
NEPI and aldosterone suppressed, CO and cardiac filling
pressures were not enhanced compared to control. This
observation suggests that the actions of chronic NEPI are
renal and adrenal specific. However, it is important to
note that NEPI has been reported to increase circulating
endothelin-1 (ET-1), a potent vasoconstrictor [27]. This
would suggest an additional novel therapeutic strategy in
CHF which would be to inhibit both NEP and endothelin-
converting enzyme (ECE) to optimize both renal and car-
diovascular function by also blocking the generation of
ET-1. Indeed, Dickstein et al [28] recently reported that
the use of a novel dual NEP and ECE inhibitor decreased
pulmonary pressures in human heart failure, confirming
the findings of Mulder et al [29] that reported decreases
in both preload and afterload, increases in cardiac out-
put and an improvement in left ventricular hypertrophy
and dilatation with inhibition of cardiac fibrosis in exper-
imental CHF with dual NEP-ECE inhibition.
Lately, there have been several studies highlighting the
importance of renal function in the progression of con-
gestive heart failure [30, 31] These investigations have
speculated that targeting the kidney to enhance renal
function in CHF may indeed delay the progression of
CHF. Indeed in a reanalysis of the SOLVD Prevention
and SOLVD Treatment Trial, Dries et al [31] concluded
that renal function was a primary determinant of com-
pensation in CHF patients, and therefore therapies capa-
ble of improving renal function may delay progression.
Importantly, we now know that preclinical heart failure
or asymptomatic LVD has been shown to have increased
risk for development of CHF and death, even when only
mild impairment of ejection fraction is present. This is ex-
tremely important since the prevalence of asymptomatic
LVD is increasing and represents almost half of all pa-
tients with impaired ventricular function [32] Therefore,
we can in part conclude from our experimental studies
that the use of NEPI or in combination with other re-
nal enhancing therapies in early stages of heart disease
can be a useful tool to delay its progression. Clearly, the
current findings warrant further studies.
CONCLUSION
The current study supports the hypothesis that chronic
oral NEPI initiated during experimental early CHF pro-
longs this compensated phase by delaying the onset of
sodium retention. This preservation of sodium home-
ostasis most likely involved potentiation of ANP or
other natriuretic factors in the kidney linked to cGMP.
In addition, in severe CHF a sustained renal action
of NEPI with a marked improvement of the impaired
natriuretic response to acute saline volume expansion
was observed. Complementing these renal actions of
chronic NEPI was the observation that the magnitude
of activation of the opposing sodium retaining factor,
aldosterone, was attenuated. The current study there-
fore supports the conclusion that chronic NEPI poten-
tiates the renal actions of endogenous ANP and delays
the onset of sodium retention during the progression to
severe CHF in an experimental model of PCHF. We fur-
ther conclude that this selective renal and adrenal effi-
cacy of chronic NEPI may have an important therapeutic
potential in progressive heart failure warranting further
studies.
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